Chainlink founder: The "net new buyers" in this bull market cycle come from the global financial system
In a recent interview, Chainlink founder Sergey Nazarov stated that due to the influx of a large number of new buyers, the current cryptocurrency market cycle is unique, which may lead to a faster adoption of RWA tokenization than initially expected by the industry.
Nazarov emphasized that participants in the recent crypto market are not just retail investors reacting to mainstream media reports on cryptocurrency price fluctuations. The new buyers come from various sectors of the global financial system, forming a very large net new buyer group.
At the same time, Nazarov predicted that RWA tokenization will be the next trend in the crypto market: "The next phase is asset tokenization. Banks see all this money flowing into ETFs and then they compete with assets against ETFs or get some funds."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
